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previous finding that FUS deposits are hypomethylated in 
FTLD-FUS but not in ALS-FUS, we have now investigated 
whether genetic or pharmacological inactivation of Pro-
tein arginine methyltransferase 1 (PRMT1) activity results 
in unmethylated FUS or in alternatively methylated forms 
of FUS. To do so, we generated FUS-specific monoclonal 
antibodies that specifically recognize unmethylated argi-
nine (UMA), monomethylated arginine (MMA) or asym-
metrically dimethylated arginine (ADMA). Loss of PRMT1 
indeed not only results in an increase of UMA FUS and a 
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a common hallmark of some cases of frontotemporal lobar 
degeneration (FTLD-FUS) and amyotrophic lateral sclero-
sis (ALS-FUS). Whether both diseases also share common 
pathological mechanisms is currently unclear. Based on our 
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decrease of ADMA FUS, but also in a significant increase 
of MMA FUS. Compared to ADMA FUS, UMA and MMA 
FUS exhibit much higher binding affinities to Transportin-1, 
the nuclear import receptor of FUS, as measured by pull-
down assays and isothermal titration calorimetry. Moreover, 
we show that MMA FUS occurs exclusively in FTLD-FUS, 
but not in ALS-FUS. Our findings therefore provide addi-
tional evidence that FTLD-FUS and ALS-FUS are caused 
by distinct disease mechanisms although both share FUS 
deposits as a common denominator.
Keywords Frontotemporal lobar degeneration (FTLD) · 
Amyotrophic lateral sclerosis (ALS) · Fused in sarcoma 
(FUS) · Arginine methylation · Neurodegeneration · Protein 
arginine methyltransferase 1 (PRMT1) · Transportin-1
Introduction
Fused in sarcoma (FUS) is a nuclear DNA/RNA-binding 
protein that is the pathological hallmark protein in abnor-
mal cytoplasmic and nuclear inclusions in some cases of 
frontotemporal lobar degeneration (FTLD) and amyo-
trophic lateral sclerosis (ALS) [24, 32, 35, 36, 54]. FTLD 
is the second most common early-onset dementia after Alz-
heimer’s disease (AD) and is clinically characterized by 
varying degrees of behavioural disturbances, personality 
changes and language impairment [33]. The neuropathol-
ogy of FTLD is classified according to the protein depos-
ited in the central nervous system. FTLD cases show patho-
logical deposition of either TAR DNA-binding protein of 
43 kDa (TDP-43) [37], microtubule associated protein tau 
(Tau) [10] or Fused in sarcoma (FUS) [32, 35, 36], hence 
they are classified as FTLD-TDP, FTLD-Tau or FTLD-
FUS [30]. Only very rare FTLD cases cannot be classi-
fied in these categories, including familial FTLD linked 
to chromosome 3 (FTD-3) [17, 18] (caused by mutations 
in the CHMP2B gene) and FTLD cases with no inclusions 
(FTLD-ni) [30]. FTLD-FUS represents about 10 % of all 
FTLD cases [31] and comprises three distinct pathological 
subtypes, namely atypical FTLD-U (aFTLD-U) [35], neu-
ronal intermediate filament inclusion disease (NIFID) [36] 
and basophilic inclusion body disease (BIBD) [32]. Genetic 
and neuropathological analyses revealed overlapping dis-
ease characteristics of ALS and FTLD [49]. Although TDP-
43 is the most common protein underlying ALS pathology, 
some rare ALS cases are associated with FUS mutations 
and show instead FUS aggregates (ALS-FUS) [24, 54].
Whether FTLD-FUS and ALS-FUS represent a patho-
logical continuum or distinct diseases remains to be elu-
cidated. Even though they share FUS deposition as the 
common denominator, there are also several obvious 
differences between the two disorders. First, ALS cases 
with FUS pathology are caused by mutations in the FUS 
gene [24, 54]. The mutations are predominantly located in 
or near the proline-tyrosine nuclear localization signal (PY-
NLS) (Fig. 1a). We and others have previously shown that 
these mutations disrupt the nuclear import of FUS via the 
nuclear import receptor Transportin-1 (TRN) and are caus-
ally related to pathogenesis of the disease [14, 20, 22, 39, 
55, 59]. In contrast, no FUS gene mutations were found in 
FTLD-FUS, except for some rare cases that presented with 
both FTLD and ALS [25], and in which no pathological 
descriptions are available and the mutations are not in the 
C-terminal region of FUS. Second, in contrast to ALS-FUS, 
cytoplasmic inclusions in FTLD-FUS also contain TRN [5, 
38, 53] as well as TAF-15 and EWS, two homologues of 
FUS that belong to the same protein family (FET family) 
[34]. Third, we have shown previously that the inclusions 
in ALS-FUS contain asymmetrically arginine dimethyl-
ated (ADMA) FUS [13]. This post-translational modifica-
tion of FUS reduces its binding to TRN and thus impairs 
import of mutant FUS into the nucleus [13, 52]. In contrast, 
FUS deposited in FTLD-FUS cases is not asymmetrically 
arginine dimethylated [13]. However, it is not yet known 
whether FUS in FTLD-FUS inclusions is unmethylated or 
shows an alternative methylation pattern that differs from 
that found in ALS-FUS or healthy controls.
Fig. 1  Characterization of monoclonal antibodies specific for UMA 
and MMA FUS. a Schematic figure of the FUS protein. FUS contains 
multiple functional domains: a QGSY-rich transcriptional activation 
domain (glutamine, glycine, serine and tyrosine rich domain), three 
RGG domains (arginine-glycine-glycine repeats); a RRM domain 
(RNA recognition motif), a ZnF domain (zinc finger domain), and 
the PY-NLS (proline-tyrosine nuclear localization signal). We gen-
erated antibodies against the differently methylated RGG3 domain 
(FUS473–503) with all nine arginines in three different forms of meth-
ylation modifications: UMA (red), MMA (blue) or ADMA (green). 
An asterisk indicates a methyl group. b Schematic representation of 
arginine methylation steps. All PRMTs (type I, II and III) are capa-
ble to add a methyl group and generate a monomethylated arginine 
(MMA). Subsequently, type I PRMTs deposit the asymmetrically 
dimethylated arginine (ADMA) signature, whereas type II PRMTs 
deposit the symmetrically dimethylated ariginine (SMDA) signa-
ture. Type III PRMT (PRMT7) can only generate MMA. c HeLa 
cells were transfected with siRNAs against FUS, EWS, TAF-15 or 
a non-targeting control and were subsequently treated with AdOx 
or left untreated. 48 h post-transfection cell lysates were analysed 
by immunoblotting with the antibodies raised against UMA FUS 
(14G1), MMA FUS (15E11) and ADMA (9G6). All of them show 
a signal at the predicted molecular weight of FUS (arrow) that dis-
appears upon knockdown of FUS. Whereas ADMA FUS anti-
body (9G6) shows immunoreactivity to untreated cells, UMA 
FUS (14G1) and MMA FUS (15E11) antibodies only reacted with 
lysates derived from AdOx-treated cells. These antibodies do not 
show cross-reactivity against EWS and TAF-15. Tubulin was used 
as a loading control and FUS, EWS and TAF-15 antibodies were 
used to examine knockdown efficiency. Asterisks: unspecific bands
▸
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Arginine methylation is mediated by protein N-arginine 
methyltransferases (PRMTs), which catalyse methyl group 
addition in two sequential steps (Fig. 1b). First, addition of 
a single methyl group generates monomethylated arginine 
(MMA). Subsequent addition of a second methyl group leads 
to a dimethylated form that can occur either as ADMA or 
symmetric N,N-dimethylarginine (SDMA) [2, 57]. In mam-
malian cells, there are nine PRMTs that all catalyse the first 
step that generates the MMA form, but different PRMTs 
are responsible for the second step (Fig. 1b). Type I PRMTs 
b c
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(which include PRMT1, PRMT2, PRMT3, PRMT4/CARM1, 
PRMT6 and PRMT8) mediate asymmetric arginine dimeth-
ylation. PRMT1 is the main type I PRMT and is responsible 
for 90 % of all ADMA enzyme activity in mammalian cells 
[50]. In contrast, type II PRMTs (PRMT5 and PRMT9) are 
responsible for SDMA [2, 57]. Finally, it has been described 
that PRMT7 exclusively catalyses the generation of MMA 
and is accordingly classified as a type III PRMT [60]. The 
MMA form has long been considered to be an intermediate 
form between the unmethylated arginine (UMA) and ADMA/
SDMA forms. However, recently it has been shown that lev-
els of MMA proteins increase after loss of PRMT1 [9] and 
that the increase of MMA is not coupled with a subsequent 
increase in ADMA modifications [48]. These findings sug-
gest that MMA is not just an intermediate form, but may have 
selective biological functions. PRMTs mostly target arginines 
in regions rich in glycines and arginines [51]. Proteins of the 
FET family (FUS, EWS and TAF-15) contain three arginine-
glycine-glycine (RGG) domains that are thought to mainly 
undergo asymmetric dimethylation by PRMT1 [1, 4, 19, 21, 
43, 46], i.e. all three proteins appear to be present mainly 
in the ADMA form under physiological conditions. Some 
MMA sites have also been reported for the FET proteins [16, 
48], whereas there is no evidence of symmetric dimethylation 
in FET proteins [46].
In the present study, we aimed at characterizing the 
methylation pattern of FUS in the pathological inclusions 
in brains of FTLD-FUS patients. To do so, we developed 
novel monoclonal antibodies specific for the UMA or 
MMA RGG3 domain of FUS. By using these antibodies 
along with a previously developed antibody specific to the 
ADMA RGG3 domain of FUS [13], we show that genetic 
or pharmacological inhibition of PRMT1 not only results 
in UMA FUS, but also in alternatively methylated MMA 
FUS. Moreover, we demonstrate that MMA FUS exhib-
its increased binding affinities to Transportin-1 similar to 
UMA FUS, whereas ADMA FUS only binds very weakly 
to Transportin-1. Finally, we provide evidence that FUS 
inclusions in FTLD-FUS contain UMA and, to a lesser 
extent, MMA FUS, in contrast to ALS-FUS where FUS 
appears to be exclusively asymmetrically dimethylated.
Materials and methods
Cell lines, cell culture, transfections and inhibitor 
treatment
Human cervical carcinoma cells (HeLa) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10 % (v/v) fetal calf serum (FCS), glutamine 
and penicillin/streptomycin at 37 °C with 5 % CO2 in a tis-
sue culture incubator.
Mouse embryonic stem (mES) cells, PRMT1 knockout 
(−/−) and wild-type controls (+/+) [44], were cultured 
with STEMPAN GMEM (Cat. No. P08-50600, PAN Bio-
tech) supplemented with 10 % (v/v) fetal bovine serum 
(PANsera Cat. No. P30-2602, PAN Biotech), penicillin/
streptomycin and leukaemia inhibitory factor (ESGRO 
Mouse LIF Medium Supplement, Cat. No. ESG1107, Mill-
ipore) at a final concentration of 103 U/ml. Adenosine-2′,3′-
dialdehyde (AdOx; Sigma) was used as a methyltransferase 
inhibitor [6] on HeLa cells for 48 h at a concentration of 
20 μM. AdOx treatment has been used to inhibit dimethyl-
ation of proteins [6] and to increase not only the UMA but 
also the MMA forms [16]. FUS, EWS and TAF-15 knock-
downs were achieved by using the ON-TARGET plus FUS 
SMARTpool L-009497, the ON-TARGET plus EWSR1 
SMARTpool L-005119 and the ON-TARGET plus TAF-15 
SMARTpool L-008930, respectively, all from Dharmacon. 
A non-targeting siRNA (ON-TARGET plus NT siRNA #3, 
D-001810-03 from Dharmacon) was used as a negative 
control. siRNAs were delivered to cells by reversed trans-
fection using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. The effect of the knock-
down was assessed 48 h post-transfection.
Generation of monoclonal antibodies and peptides
Monoclonal antibodies were generated in LOU/C rats or 
C57BL/6 mice against ovalbumin-conjugated FUS473–503 pep-
tide (RGGRGGYDRGGYRGRGGDRGGFRGGRGGGDR), 
corresponding to the RGG3 domain of FUS, in which all 
nine arginines were either unmethylated (UMA FUS) or 
monomethylated (MMA FUS) (Fig. 1a). The ADMA FUS 
antibody (9G6) was previously described and characterized 
[13]. Rat monoclonal antibodies were also raised against 
the ADMA RGG3 domain of EWS (EWS564–583 GRGG-
PGGMRGGRGGLMDRGG) and TAF-15 (TAF-15458–477 
DRGGGYGGDRGGGYGGDRGG), using ovalbumin-con-
jugated peptides. All antibodies were produced by standard 
procedures.
Peptides were synthesized by Peps4LS GmbH, or Pep-
tide Specialty Laboratories GmbH. For the methylated 
peptides, modified amino acids (ADMA or MMA, respec-
tively) were used instead of arginine during synthesis. 
Peptides were purified by gradient HPLC-purification on 
a C-18 preparative HPLC column and the single fractions 
were characterized by UV trace of an analytical HPLC 
spectrum. Only fractions with a >90 % purity were com-
bined and confirmed by MALDI mass spectrometry.
The hybridoma supernatants were first screened by 
ELISA using the corresponding ADMA, MMA or UMA 
peptides as antigens. Next, they were assessed in immu-
noblotting of cell culture lysates of HeLa cells. The UMA 
FUS-specific clone 14G1 (Rat IgG 2a) showed the best 
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performance, for MMA FUS-specificity, clone 15E11 (Rat 
IgG 2a) was chosen. To confirm the results obtained with 
these antibodies, we generated and selected an additional 
monoclonal UMA FUS-specific antibody, (2A3; Mouse 
IgG 2b), and an additional monoclonal MMA FUS-specific 
antibody (18E11; Rat IgG 2a). Similarly, we selected the 
best ADMA EWS-specific clone (21B1; Rat IgG1) and the 
best ADMA TAF-15-specific clone (Rat 12F11; Rat IgG 
2c). All hybridomas were subcloned at least twice to ensure 
monoclonality and stability of the clones. Where necessary, 
antibodies were purified via protein G column.
Other antibodies
The following commercial antibodies were used: EWS-
specific mouse monoclonal antibody G5 sc28327 (Santa 
Cruz) and rabbit polyclonal antibody H-60 sc28865 (Santa 
Cruz); FUS-specific mouse monoclonal antibody 4H11 
(Santa Cruz) and rabbit polyclonal A300-294A (Bethyl) 
and HPA008784 (Sigma); HA-specific mouse monoclo-
nal antibody HA.11 (Covance); MonomethylArginine 
(R*GG)-specific rabbit monoclonal antibody D5A12 
#8711 (Cell Signalling); MonomethylArginine-specific 
monoclonal rabbit antibody Me-R4-100 #8015 (Cell Sig-
nalling); PRMT1-specific rabbit monoclonal EPR3292 
(Abcam); TAF-15-specific rabbit antibody TAF15-308A 
(Bethyl), rabbit polyclonal antibody SAB2102361 (Sigma) 
and mouse monoclonal antibody H00008148 (Abnova); 
Transportin-specific rabbit antibody clone D45 (Sigma); 
α-Tubulin-specific mouse monoclonal antibody clone B-5-
1-2 (Sigma).
The secondary antibodies for immunoblotting were 
horseradish peroxidase (HRP)-conjugated goat anti-mouse, 
anti-rabbit or anti-rat IgG (Promega) or mouse anti-rat 
IgG2a, IgG2b and IgG2c (home made).
Protein analysis
Total cell lysates were prepared in ice-cold RIPA buffer 
(50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 % NP-40, 
0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sul-
phate) freshly supplemented with Protease inhibitor Cock-
tail (Roche), sonicated (Bioruptor from Diagenode), and 
their protein concentration was determined by BCA pro-
tein assay (Interchim). Lysates were then supplemented 
with SDS–PAGE sample buffer (62.5 mM Tris–HCl pH 
6.8, 2 % sodium dodecylsulfate, 0.03 % bromophenol 
blue, 143 mM β-mercaptoethanol, 10 % glycerol) and 
boiled for 5 min.
For immunoprecipitation, whole mES cell extracts were 
prepared in mild lysis buffer (50 mM Tris–HCl pH 8.0, 
150 mM NaCl, 2 mM EDTA, 1 % Triton X-100) for the 
immunoprecipitation of FUS, EWS and MMA proteins, 
or in RIPA buffer for the immunoprecipitation of TAF-15. 
The lysates were pre-cleared with washed Protein G Sepha-
rose beads (Thermo Scientific) for 30 min at 4 °C, followed 
by incubation for 2 h at 4 °C with the antibody of interest 
coupled to Protein G beads. The beads were washed three 
times with the lysis buffer and boiled in 2× SDS-PAGE 
sample buffer to elute bound proteins.
Proteins were separated by SDS-PAGE and transferred 
to PVDF membranes (Imobilon-P, Millipore). Membranes 
were blocked in 5 % powdered milk in TBST and incu-
bated in primary antibody overnight at 4 °C. Membranes 
were probed with HRP-coupled secondary antibodies and 
developed with the chemiluminescence detection reagents 
ECL or ECL plus (both from Thermo Scientific).
To examine solubility of FET proteins, a sequential 
extraction was performed as described [11] with some 
modifications. Briefly, cells were washed with PBS, lysed 
in cold RIPA buffer and sonicated. Lysates were centri-
fuged at 180,000g for 30 min at 4 °C. After removal of the 
RIPA-soluble fraction, RIPA-insoluble pellets were washed 
three times with RIPA buffer, sonicated and re-pelleted. 
Insoluble pellets were dissolved in urea buffer (7 M urea, 
2 M thiourea, 4 % CHAPS, 30 mM Tris, pH 8.5). Both sol-
uble and insoluble fractions were supplemented with SDS-
PAGE sample buffer and boiled.
Neuronal culture, transfection and treatment
Cortical neurons were prepared from embryonic day 18 
Sprague–Dawley rat embryos and cultivated in Neuroba-
sal medium (ThermoFisher) supplemented with 2 % B27 
(ThermoFisher), 1 % penicillin/streptomycin, 0.25 % glu-
tamine and 0.125 % glutamate as described previously 
[41]. Cells were harvested 7 days later (DIV7) in RIPA 
buffer. Adox (10 µM) treatment was started 48 h prior to 
harvesting.
In vitro pull‑down assay
In vitro pull-down assays were performed as previously 
described [13]. Briefly, N-terminally biotinylated UMA-
FUS473–503, MMA-FUS473–503 and ADMA-FUS473–503 pep-
tides were immobilized on streptavidin Sepharose beads 
(GE Healthcare) and blocked in wash buffer (20 mM 
sodium phosphate buffer pH 7.4, 150 mM KCl, 0.5 mM 
EDTA, 5 mM MgCl2, 10 % glycerol, 1 mM DTT) supple-
mented with 0.5 mg/ml BSA. The peptide-coupled beads 
were then incubated with increasing amounts of recombi-
nant TRN–His6 or His6–GST for 1–3 h at 4 °C. The beads 
were washed, boiled in SDS-PAGE sample buffer and 
eluted proteins were resolved by SDS-PAGE and visual-
ized by staining with GelCode Blue Stain Reagent (Thermo 
Scientific).
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Protein expression and purification
Escherichia coli (E. coli) BL21 (DE3) cells were trans-
formed with a modified version of the pETM11 expres-
sion vector (including a His6, protein A tag and a tobacco 
etch virus–TEV- protease cleavage site) harbouring the E. 
coli codon optimize gene of Transportin-1. One litre of 
M9 minimal medium was inoculated, cultures were grown 
for 2 days at 25 °C, diluted to OD 1.0 and induced with 
0.5 mM IPTG for either 6 h at 25 °C or 14 h at 19 °C. 
Cells were resuspended in 30 ml purification buffer 
[110 mM potassium acetate, 20 mM Hepes, pH 8.0, 2 mM 
MgCl2, 2 mM β-mercaptoethanol (BME), 5 % (v/v) glyc-
erol and 20 mM Imidazole], sonicated and applied to a 
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Fig. 2  Loss of PRMT1 elicits a switch in the methylation pattern 
of FUS from ADMA to MMA and UMA. a Whole cell lysates of 
PRMT1 knockout (PRMT1 −/−) and wild-type (PRMT1 +/+) mES 
cells (duplicates from two independent experiments) were prepared 
and immunoblotted with antibodies specific for ADMA FUS (9G6), 
MMA FUS (15E11) and UMA FUS (14G1). A decrease in ADMA 
FUS paralleled by an increase in UMA and MMA FUS is observed in 
PRMT1 −/− mES cells. Membranes were blotted with anti-Tubulin 
and anti-total FUS antibodies to visualize equal loading and with a 
PRMT1-specific antibody to confirm PRMT1 knockout. Asterisks 
indicate unspecific bands. b, c Whole cell lysates were subjected to 
immunoprecipitation (IP) with an anti-FUS antibody and an isotype 
control antibody. Precipitated proteins were analysed by immunob-
lotting (IB) with a general anti-MMA antibody (D5A12) that recog-
nizes monomethylated RGG motifs. This demonstrates an increase 
in MMA FUS in PRMT1 −/− cells (top panel). The input (whole 
cell lysates) is shown in the left panel. Equal amounts of FUS pro-
tein were immunoprecipitated from PRMT1 +/+ and PRMT1 −/− 
cells (bottom panel). The same immunoprecipitated material was 
also immunoblotted with another anti-MMA antibody (Me-R4-100) 
raised against monomethylated arginine. This confirmed an increase 
in MMA FUS upon PRMT1 knockout (PRMT1 −/−). d Immunopre-
cipitation (IP) of monomethylated proteins followed by immunoblot-
ting (IB) for FUS confirmed an increase of MMA FUS in PRMT1 
−/− cells
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Ni–NTA agarose column according to the manufacturers 
instruction. The protein was eluted with the same buffer 
including 200 mM imidazole and further purified via 
size exclusion chromatography on an ÄKTA pure sys-
tem equipped with HiLoad 16/600 Superdex 200 pg (for 
Transportin-1; column GE Healthcare) using purification 
buffer. The protein-containing fractions were merged and 
incubated with 0.2 mg TEV protease overnight at 4 °C. 
On the next day, the protein solution was applied on the 
Ni–NTA agarose column to remove the tag and the His6-
tagged TEV protease. Protein was freshly prepared for 
ITC runs, stored at 4 °C, and buffer exchanged prior the 
measurements on an ÄKTA pure system equipped with 
a HiPrep (26/10) desalting column (GE Healthcare) pre-
equilibrated with freshly prepared ITC interaction buffer 
(50 mM Tris, 150 mM NaCl, 2 mM tris(2-carboxyethyl)
phosphine, pH 6.7). Protein solution was concentrated 
using Amicon Ultra-15 (Millipore, 3 kDa molecular 
weight cut-off) centrifugal filter units to the desired 
concentrations.
Isothermal titration calorimetry (ITC)
Binding affinities of FUS RGG3 peptides to Transpor-
tin-1 were determined using a VP-ITC Microcal calo-
rimeter (Microcal, Northhampton, USA) at 25 °C with a 
stirring speed of 300 rpm. Titrations employed an initial 
delay of 300 s, a 9.6 µl initial injection volume followed 
by 300 s delay, and 35 × 19.6 µl injections of FUS pep-
tides into the Transportin-1 solution. Concentrations of 
Transportin-1 were 10 µM for the UMA and MMA RGG 
peptides and 15 µM for the ADMA peptide, respectively. 
Concentrations of UMA RGG peptide were 100, 120 µM 
for MMA RGG peptide and 150 µM for the ADMA pep-
tide. The ITC datasets were analysed with the program 
MicroCal Origin software version 7.0 assuming a single 
binding site.
Immunohistochemistry and immunofluorescence 
on human post mortem tissue
Human post mortem central nervous system (CNS) tis-
sue was provided by the Neurobiobank Munich, Ludwig-
Maximilians-University (Munich, Germany) and the Brain 
Banks affiliated with the University of Tübingen, Germany, 
University of British Columbia, Canada, and University of 
Oxford, United Kingdom. Consent for autopsy and research 
was obtained from the legal representative in accordance 
with local institutional ethical review committees.
Studied FUS-opathy cases with robust pathology in 
selected neuroanatomical regions included aFTLD-U 
(n = 4), BIBD (n = 2), NIFID (n = 3) and four ALS-FUS 
cases with three different FUS mutations, p.R521C (n = 2), 
p.P525L (n = 1), and p.R514S/E516 V (n = 1).
Immunohistochemistry was performed on ~5 µm thick 
formalin fixed paraffin embedded sections using the Ven-
tana BenchMark XT automated staining system (Ventana, 
Tuscon, AZ) with the iVIEW DAB detection kit. Boiling of 
sections in citrate buffer (pH 6) for 20 min was performed as 
antigen retrieval for all stainings and incubation of primary 
antibodies was performed overnight at 4 °C. For double-label 
immunofluorescence, the secondary antibodies were Alexa 
Fluor 594 conjugated anti-rabbit and or Alexa Fluor 488 
conjugated anti-rat IgG (Invitrogen, 1:500). Hoechst 33342 
or DAPI was used for nuclear counterstaining. Sections were 
treated with Sudan black to reduce autofluorescence.
Results
Generation and characterization of UMA FUS‑ 
and MMA FUS‑specific antibodies
To characterize the methylation patterns of FUS in post mor-
tem brains of FTLD and ALS patients we developed highly 
selective monoclonal antibodies against the differentially 
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Fig. 3  Neuronal FUS switches its methylation pattern from ADMA 
to MMA and UMA upon treatment with AdOx. Rat cortical neurons 
(DIV 7) were treated with AdOx (10 µM) for 48 h or left untreated 
and examined by immunoblotting with antibodies specific for UMA 
FUS (14G1), MMA FUS (15E11) and ADMA FUS (9G6). In line 
with the results observed in HeLa and mES cells, UMA FUS (14G1) 
and MMA FUS (15E11) were selectively increased upon treatment 
with AdOx, whereas ADMA FUS was decreased. Tubulin was used 
as a loading control. Duplicates from two independent experiments 
are shown. Asterisks: unspecific bands
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methylated RGG3 domain of FUS (peptide epitope FUS473–
503; Fig. 1a). This domain is localized next to the PY-NLS and 
contains nine arginine residues that can be asymmetrically 
dimethylated [40, 46]. UMA FUS473–503 and MMA FUS473–503 
specific antibodies were newly developed for this study, 
whereas the ADMA FUS-specific antibody 9G6 has been 
previously developed and characterized [13] (Fig. 1a). Hybri-
doma supernatants were screened by ELISA against all pep-
tides, and those with a strong selective signal but no signifi-
cant cross-reactivity to the other peptides were further tested 
by immunoblotting on HeLa cells lysates. To validate speci-
ficity, we performed siRNA-mediated FUS knockdowns and 
treated cells with the methylation inhibitor AdOx (adenosine-
2′-3′-dialdehyde). AdOx is a global methyltransferase inhibi-
tor that reduces the ADMA of proteins [6] and conversely 
increases the UMA but also the MMA forms [16]. After 
screening a large number of antibodies, we selected an UMA 
FUS (clone 14G1) and MMA FUS (clone 15E11) antibody 
that recognized a specific band in AdOx-treated HeLa cells 
that was selectively absent upon knockdown of FUS but not 
of the other FET family members TAF15 or EWS (Fig. 1c). 
We also used our previously described ADMA FUS-specific 
antibody (clone 9G6) [13], which shows a signal in untreated 
cells that disappears upon treatment with AdOx or knock-
down of FUS (Fig. 1c).
Genetic and pharmacological reduction of PRMT1 
results in a switch from asymmetrically dimethylated 
FUS to unmethylated and monomethylated FUS
After having verified specificity of the UMA, MMA and 
ADMA FUS antibodies, we used them to investigate the 
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Fig. 4  Characterization of novel monoclonal antibodies specific for 
ADMA EWS and ADMA TAF-15. a Schematic figure of EWS and 
TAF-15 and their domains. Note the similarity to FUS (Fig. 1a). Anti-
bodies were generated against the ADMA RGG3 domain of EWS and 
TAF15 (sequence of the peptides use for immunization indicated in 
the figure). b, c: siRNAs against FUS, EWS, TAF-15 or a non-tar-
geting control were transfected into HeLa cells, and cells were either 
left untreated or treated with AdOx. 48 h post-transfection, lysates 
were analysed by immunobloting with the antibody raised against 
ADMA EWS (21B1) or TAF15 (12F11). The antibodies label one 
specific band at the predicted molecular weight of EWS or TAF15 
(arrow) that is reduced or disappears upon knockdown of EWS or 
TAF15 or AdOx treatment demonstrating specificity of these antibod-
ies for ADMA EWS and ADMA TAF-15. Tubulin was used as a load-
ing control and EWS and TAF-15 antibodies were used to examine 
knockdown efficiency
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methylation status of FUS in a cellular model of hypometh-
ylation, namely mouse embryonic stem cells (mES) that 
lack PRMT1 [44]. This approach allowed us to investigate 
how the pattern of FUS methylation changes upon loss of 
a major PRMT. Using our new antibodies, we observed 
a strong decrease in ADMA FUS and a corresponding 
increase of UMA FUS in PRMT1 knockout (−/−) cells 
(Fig. 2a). The signal of ADMA FUS did not completely 
disappear in the PRMT1 knockout cells, indicating that, 
although PRMT1 is the main enzyme responsible for 
methylation of FUS, other PRMTs might also be involved 
in asymmetric dimethylation of FUS. Interestingly, upon 
knockout of PRMT1, there was also a significant increase 
of MMA FUS, as demonstrated by the increased signal 
with the 15E11 antibody (Fig. 2a). To further confirm this 
result, we performed an immunoprecipitation of FUS fol-
lowed by immunoblotting with a commercially available 
anti-MMA antibody (D5A12), which recognizes a large 
number of monomethylated proteins [9]. This confirmed an 
increase in MMA FUS in PRMT1 knockout cells (Fig. 2b). 
This finding was further confirmed using another anti-
MMA antibody (Me-R4-100) raised against monomethyl-
ated arginine (Fig. 2c). Furthermore, the reciprocal immu-
noprecipitation with the anti-MMA antibody (D5A12) 
followed by immunoblotting for FUS also confirmed an 
increase in MMA FUS in PRMT1 knockout cells (Fig. 2d). 
Remarkably, we did not detect signals with the UMA FUS 
and MMA FUS-specific antibodies, even after long expo-
sure, in both wild-type (+/+) mES cells (Fig. 2a) and 
untreated HeLa cells (Fig. 1c). Only upon enrichment after 
immunoprecipitation we detected a small amount of MMA 
FUS in wild-type mES cells (Fig. 2b–d) suggesting that 
under physiologic conditions these species are much less 
abundant than ADMA FUS.
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Fig. 5  Altered methylation pattern of EWS and TAF-15 upon loss 
of PRMT1. a Whole cell lysates of PRMT1 knockout (PRMT1 −/−) 
and wild-type (PRMT1 +/+) mES cells (duplicates from two inde-
pendent experiments) were prepared and immunoblotted with anti-
bodies specific for ADMA EWS (21B1). A decrease in ADMA EWS 
is observed in PRMT1 −/− cells. All lysates were blotted with anti-
Tubulin and anti-total EWS antibodies to visualize equivalent load-
ing and a PRMT1-specific antibody to verify the PRMT1 knockout. 
b The same lysates were immunoblotted with the ADMA TAF15 
(12F11) antibody. A strong decrease in ADMA TAF-15 is observed 
in PRMT1 −/− cells. c, d Whole mES cell lysates were subjected 
to immunoprecipitation (IP) with a general anti-MMA antibody 
(D5A12) and an isotype control antibody. Samples were analysed 
by immunoblotting (IB) with an anti-EWS or anti-TAF-15 antibody. 
This demonstrated an increase in MMA EWS and MMA TAF-15 in 
PRMT1 −/− cells. Asterisk in d represent immunoglobulin bands
 Acta Neuropathol
1 3
To exclude cross-reactivity of our antibodies against 
other methylation patterns in PRMT1 knockout cells, we 
performed an antigen absorption assay with the three differ-
ent peptides used for immunization (Supplementary Fig. 1a, 
b). The specific band recognized by the 14G1 UMA FUS 
antibody selectively disappeared upon preincubation of the 
antibody with the UMA FUS473–503 peptide, but not with the 
MMA FUS473–503 or the ADMA FUS473–503 peptide (Sup-
plementary Fig. 1a). Likewise, the signal obtained with the 
15E11 MMA FUS antibody selectively disappeared upon 
preincubation of the antibody with the MMA FUS473–503 
peptide but not with the others (Supplementary Fig. 1b). 
These results confirm the selectivity of the 14G1 and 15E11 
antibodies and, importantly, demonstrate the lack of cross-
reaction with the other methylation patterns.
To address whether a similar change in the pattern of 
FUS methylation also occurs in neurons, we treated rat 
cortical neurons with AdOx and analysed the lysates with 
the FUS methylation-specific antibodies. In line with our 
results in HeLa cells, inhibition of arginine methylation 
resulted in a significant and specific increase of UMA and 
MMA FUS (Fig. 3) demonstrating that FUS methylation is 
highly similar in neurons and peripheral cells.
Loss of PRMT1 increases monomethylation of all 
members of the FET protein family, but does not affect 
their solubility
Since EWS and TAF-15, the two other members of the 
FET protein family, have the same domain structure as 
FUS and their RGG domains are known to be asymmetri-
cally dimethylated [1, 4, 21, 43], we investigated whether 
they are also monomethylated upon loss of PRMT1. To 
do so, we generated antibodies against the ADMA RGG3 
domain of EWS and TAF-15 (Fig. 4a). Again, hybridoma 
supernatants were screened for their specificity first by 
an ELISA against the peptide used for immunization and 
second by immunoblotting of HeLa cells lysates (Fig. 4b, 
c). We selected antibodies specific for ADMA EWS 
(clone 21B1) and ADMA TAF-15 (clone 12F11). Both 
detected a band at the predicted molecular weight that 
was reduced or selectively disappeared after treatment 
with AdOx or knockdown of EWS or TAF-15 (Fig. 4b, 
c). Using these antibodies, we observed a strong decrease 
in ADMA EWS and ADMA TAF-15 in PRMT1 knockout 
cells (Fig. 5a, b), as observed for ADMA FUS (Fig. 2a). 
To test whether EWS and TAF-15 also become mono-
methylated upon loss of PRMT1, we immunoprecipi-
tated monomethylated proteins from whole cell lysates 
of wild-type or PRMT1 knockout mES cells and subse-
quently immunoblotted for EWS and TAF-15. Like for 
FUS, we observed an increase in MMA EWS and MMA 
TAF-15 upon knockout of PRMT1 (Fig. 5c, d). Thus, 
we conclude that all three FET proteins (FUS, EWS and 
TAF-15) are mainly asymmetrically dimethylated by 
PRMT1 under physiological conditions, whereas a shift 
towards monomethylated arginine (MMA) is observed 
upon loss of PRMT1.
Next, we investigated whether changes in the methyla-
tion status of FET proteins may affect their solubility. To 
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Fig. 6  Hypomethylation does not change the aggregation propensity 
of the FET proteins. a HeLa and HEK cells treated or untreated with 
AdOx and wild-type and PRMT1 knockout mES cells were fraction-
ated in a RIPA soluble (S) and insoluble fraction (I). The insoluble 
fraction was dissolved in urea buffer. Immunobloting against FUS, 
EWS and TAF-15 shows that all FET proteins are predominantly 
RIPA soluble in all cells investigated. After treatment with AdOx or 
in PRMT1 knockout cells, the proportion of soluble and insoluble 
protein does not change, suggesting that hypomethylation does not 
affect the FET protein’s aggregation propensity. b Rat cortical neu-
rons treated or untreated with AdOx were fractionated into RIPA 
soluble (S) and insoluble (I) fractions. Again the proportion of solu-
ble and insoluble protein does not change upon AdOx treatment, sug-
gesting that hypomethylation does not affect aggregation propensity 
of FET proteins
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do so, we performed fractionation experiments in HeLa, 
HEK cells (untreated or treated with AdOx), mES cells 
(wild-type and PRMT1 knockout cells) and primary corti-
cal neurons. After inhibition of arginine methylation none 
of the FET proteins shifted to the insoluble fraction in 
all cells investigated, including primary cortical neurons 
(Fig. 6a, b). These findings suggest that the methylation 
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Fig. 7  UMA and MMA FUS have a higher affinity to Transpor-
tin-1 (TRN) than ADMA FUS. a Schematic representation of the 
three different biotinylated synthetic peptides comprising the RGG3 
domain of FUS (FUS473–503) with three different methylation pat-
terns: UMA (red), ADMA (green) or MMA (blue). b Biotinylated 
FUS473–503 peptides shown in (a) were immobilized on streptavidin 
beads and an in vitro pull-down assay was performed with recombi-
nant TRN (TRN-His6) or His6-GST as a control. TRN bound to the 
FUS473–503 peptides was visualized by SDS-PAGE and Coomassie 
staining (upper panel). The lower panel shows that equal amounts of 
streptavidin beads and FUS473–503 peptide were present in all samples. 
c The efficiency of the TRN pulldown was quantified by measuring 
the intensity of the TRN bands in the Coomassie gels of three inde-
pendent pulldown experiments. The values are expressed in arbitrary 
units (AU) relative to the band with the highest intensity. Error bars 
indicate standard deviation (SD)
Table 1  TRN binding to FUS. dissociation constants (kD) as deter-
mined by isothermal titration calorimetry
Sample kD (µM)
UMA FUS473–503 0.7 ± 0.4
MMA FUS473–503 4.5 ± 0.9
ADMA FUS473–503 12.4 ± 10.7
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status of FET proteins does not directly affect their aggre-
gation propensity.
Unmethylated and monomethylated FUS have a higher 
affinity for Transportin‑1
A remarkable difference in the neuropathology of FTLD-
FUS and ALS-FUS is that the nuclear import receptor of 
the FET proteins, Transportin-1 (TRN) is present in the 
inclusions in FTLD-FUS but not in ALS-FUS [5, 38, 53]. 
Moreover, FUS is hypomethylated in FTLD-FUS cases 
[13]. We have previously shown that ADMA FUS has a 
significantly lower affinity to TRN than UMA FUS [13]. 
However, the affinity of MMA FUS to TRN is unknown. 
Therefore, we performed in vitro pull-down assays with 
recombinant TRN and the three biotinylated FUS473–503 
peptides (ADMA, MMA and UMA, Fig. 7a). Interestingly, 
both UMA and MMA FUS473–503 peptides showed a much 
higher affinity to TRN than ADMA FUS473–503 (Fig. 7b, c).
To further confirm the distinct affinity of the differently 
methylated RGG3 FUS peptides to TRN, we performed 
isothermal titration calorimetry (ITC). Increasing methyla-
tion of the synthetic RGG3 peptide (FUS473–503) resulted 
in increasing loss of binding affinity, corresponding to 
increased dissociation constants (kD), for TRN (Table 1; 
Supplementary Fig. 2). This confirmed that the UMA and 
MMA RGG3 domains have a much higher affinity for TRN 
than the ADMA form.
Fig. 8  UMA FUS antibody 
labels inclusions in FTLD-FUS 
but not in ALS-FUS. Double-
label immunofluorescence with 
UMA FUS antibody 14G1 
(green), a pan-FUS antibody 
(red) and nuclear counterstain-
ing with Hoechst (blue). The 
characteristic FUS-positive 
cytoplasmic and intranuclear 
inclusions in aFTLD-U (dentate 
gyrus), NIFID (dentate gyrus) 
and BIBD (frontal cortex) are 
robustly co-labelled by the 
UMA FUS-specific antibody, 
in striking contrast to the FUS-
positive inclusions in ALS-FUS 
cases with different mutations, 
which are not labelled with the 
UMA FUS antibody. Scale bar 
50 µm
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Inclusions in FTLD‑FUS but not ALS‑FUS patients 
contain unmethylated and monomethylated FUS
To investigate whether the observed shift in the methyla-
tion pattern of FUS towards UMA and MMA FUS that we 
observed in PRMT1 knockout cells (Fig. 2) also occurs in 
FUS-opathies, we stained human CNS tissue from ALS-
FUS, FTLD-FUS and controls with the antibodies spe-
cific to differentially methylated FUS. We have previously 
shown that FUS inclusions in all FTLD-FUS subtypes do 
not contain ADMA FUS, whereas inclusions in ALS-FUS 
cases are labelled with the ADMA FUS-specific antibody 
[13]. The inverse result was now seen with the UMA FUS 
antibody 14G1, which showed a robust and consistent co-
staining of FUS-positive cytoplasmic and intranuclear 
inclusions in all FTLD-FUS subtypes (Figs. 8, 9), but not 
in ALS-FUS (Fig. 8). No staining was observed in a con-
trol or a FTLD-TDP case, demonstrating the selectivity 
of the UMA FUS signal (Fig. 9). Notably, nuclei in cases 
and controls were not labelled with the UMA FUS-specific 
antibody, implying that UMA FUS is not present under 
physiological conditions.
Despite some background staining, the MMA FUS 
antibody 15E11 revealed clear labelling of a subset of 
FUS inclusions in all FTLD-FUS cases (Figs. 10, 11) 
but not in ALS-FUS (Fig. 10). Labelling of inclusions 
was not observed in a control or a FTLD-TDP case, also 
demonstrating the selectivity of the MMA FUS signal 
(Fig. 11). These findings are in line with the cell culture 
experiments where blockage of ADMA of FUS is paral-
leled by the presence of MMA FUS. We confirmed these 
results with a second UMA FUS-specific antibody (2A3; 
Supplementary Fig. 3) and a second MMA FUS-specific 
antibody (18E11; Supplementary Fig. 4), which showed 
labelling of the FTLD-FUS inclusions similar to that 
observed by the 14G1 (UMA FUS) and 15E11 (MMA 
FUS) antibodies. Moreover, the UMA FUS and MMA 
FUS-positive inclusions co-stain with TRN, a protein spe-
cifically deposited in FTLD-FUS inclusions [5, 38, 53] 
(Supplementary Fig. 5).
Taken together, we demonstrate that the inclusions are 
clearly labelled with both the UMA FUS and the MMA 
FUS antibodies, which further supports our hypothesis 
of impaired FUS methylation regulation in FTLD-FUS 
pathogenesis.
Discussion
The main finding in the present study is that aggregated 
unmethylated and monomethylated FUS are a hallmark 
of FTLD-FUS. This reveals another significant difference 
between FTLD-FUS and ALS-FUS (Table 2) and sup-
ports the hypothesis that different mechanisms underlie the 
pathogenesis of both diseases, even though both disorders 
share FUS accumulation as a common feature.
Fig. 9  UMA FUS immunohistochemistry in FTLD-FUS brains. 
Immunohistochemical detection of UMA FUS aggregates in the fron-
tal cortex of a FTLD-FUS (NIFID) case using the 14G1 antibody. a 
In the FTLD-FUS case numerous neuronal cytoplasmic inclusions 
are found in the outer cortical layers (mainly layers II and III) of the 
superior frontal gyrus (insert represents zoomed stippled rectangle). 
b, c UMA aggregates are not detectable in the frontal cortex of a 
control case or a FTLD-TDP case. d–g Shapes of cytoplasmic UMA 
FUS inclusions vary between ring-like (violet arrows), dot-like (black 
arrow), crescent (red arrows) and triangular (green arrows). Scale 
bars in a–c represent 200 µm, scale bars in d–g 50 µm
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Two principal types of posttranslational modifications 
(PTMs) have been described for the FET proteins: argi-
nine methylation and phosphorylation [8, 15, 23, 26]. Both 
methylation and phosphorylation can affect the nuclear-
cytoplasmatic localization of FET proteins [3, 7, 13, 14, 28, 
52] and they may also be involved in the regulation of RNA/
DNA binding, protein–protein interaction [29], stress gran-
ule recruitment [56] or the solubility of the FET proteins 
[42, 45, 58]. Furthermore, it has recently been described 
that phosphorylation of the N-terminus of FUS mediates its 
cytoplasmic translocation after DNA damage [8].
The hypothesis that FUS could be hypomethylated in 
FTLD-FUS emerged from our previous finding with an 
antibody specific for ADMA FUS. We could show that 
inclusions in ALS-FUS patients were labelled with this 
antibody, but inclusions in FTLD-FUS cases were not 
[13]. This implied that inclusions in FTLD-FUS do not 
contain ADMA FUS. However, the experiments did not 
exclude that the absent staining was caused by differ-
ent conformations of FUS in inclusions in FTLD-FUS, 
with the epitope for our ADMA FUS antibody being 
inaccessible.
To model the hypomethylated state that we hypothesise 
to occur in FTLD-FUS, we used mES cells lacking PRMT1 
[44]. Using this cellular model, we investigated how the 
pattern of methylation of FUS and the other FET proteins 
changes when FET proteins are not properly methylated by 
PRMT1. As expected, we observed a decrease in ADMA 
FUS, EWS and TAF-15 and an increase in UMA FUS 
upon PRMT1 knockout. Remarkably, we also observed 
Fig. 10  MMA FUS antibody 
labels inclusions in FTLD-FUS 
but not in ALS-FUS. Double-
label immunofluorescence with 
MMA FUS antibody 15E11 
(green), a pan-FUS antibody 
(red) and nuclear counter-
staining with Hoechst (blue). 
The majority of FUS-positive 
cytoplasmic and intranuclear 
inclusions in aFTLD-U (dentate 
gyrus), NIFID (dentate gyrus) 
and BIBD (frontal cortex) are 
co-labelled by the MMA FUS-
specific antibody, in striking 
contrast to the FUS-positive 
inclusions in ALS-FUS cases 
with different mutations, which 
are not labelled with the MMA 
FUS antibody. Scale bar 50 µm
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an increase in MMA FET proteins. Thus, all FET proteins 
adopt differentially methylated forms (UMA and MMA) 
upon loss of PRMT1 activity.
Little is known about the role of MMA as a regulator of 
protein function but, interestingly, several other RNA-bind-
ing proteins besides FUS can be monomethylated [16, 48], 
which implies that this PTM probably plays a pivotal role 
in RNA-binding protein regulation. Previous studies identi-
fied rare MMA sites in EWS [4, 43] and, more recently, two 
reports independently identified proteins that contain MMA 
in human cell lines through a proteomic approach [16, 48]. 
Both studies applied an immunoaffinity purification of pro-
teins containing MMA, followed by identification of these 
Fig. 11  MMA FUS immunohistochemistry in FTLD-FUS brains. 
Immunohistochemical detection of MMA FUS in the superior fron-
tal gyrus of a FTLD-FUS (NIFID) case using the 15E11 antibody. a 
In the FTLD-FUS case neuronal cytoplasmic inclusions are mainly 
found in the outer cortical layers (layers II and III); (insert repre-
sents zoomed stippled rectangle). b, c 15E11 positive inclusions are 
not detectable in the frontal cortex of a control or a FTLD-TDP case. 
d–g As seen for UMA FUS (Fig. 9) cytoplasmic inclusions can be 
dot-like (black arrow), ring-like (violet arrow), crescent (red arrow) 
or triangular (green arrow). There is a non-specific staining of axonal 
tracks in the FTLD-FUS (h), the control (i) and a FTLD-TDP case 
(j), which is most obvious in the subcortical white matter (asterisks in 
h, i and j). This background staining most likely reflects cross-reac-
tivity with additional MMA proteins (besides MMA FUS) as shown 
by this antibody also in immunoblots (Fig. 1c; Fig. 2a). Scale bars 
in a–c, represent 200 µm, scale bars in d–g 50 µm, scale bars in h–j 
500 µm
Table 2  Comparison of FTLD-FUS and ALS-FUS pathology
Table modified from [12]
FTLD-FUS ALS-FUS References
Deposition of FUS ✓ ✓ [24, 32, 35, 36, 54]
FUS mutations – ✓ [24, 54]
Deposition of Trans-
portin-1
✓ – [5, 38, 53]
Deposition of EWS ✓ – [34]
Deposition of TAF-15 ✓ – [34]
ADMA FUS – ✓ [13]
MMA FUS ✓ – This study
UMA FUS ✓ – This study
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proteins by mass spectrometry [16, 48]. The most common 
MMA-containing proteins identified were those involved 
in RNA processing and transcriptional regulation. Strik-
ingly, among the MMA proteins all three FET proteins 
were found. Interestingly, Guo et al. [16] also describes a 
tissue-specific distribution of MMA proteins and report that 
in mouse brains most MMA proteins are involved in synap-
tic transmission. Whether MMA sites are merely a transi-
tion state between UMA and ADMA or indeed a distinct 
posttranslational modification with its own biological func-
tion is still unknown. This latter hypothesis is supported 
by the fact that there is a methyltransferase, PRMT7, that 
only catalyzes monomethylation [60]. Moreover, it has 
been suggested that a still uncharacterized MMA-specific 
demethylase may exist [48]. Monomethylation of lysines is 
already known to have its own biological function, namely 
labelling proteins for degradation through the methyl 
degron [27].
A still unanswered question is how the hypomethylated 
state may arise in brains of FTLD-FUS patients. One pos-
sible explanation would be a deficiency in PRMT activ-
ity, but this hypothesis seems unlikely, given that these 
enzymes methylate a broad range of substrates besides FET 
proteins, that are not deposited in FTLD-FUS [38]. Fur-
thermore, no mutations in PRMT genes have been found in 
FTLD-FUS cases [47]. However, only three PRMTs have 
been investigated (PRMT1, PRMT3 and PRMT8), hence 
the remaining PRMTs and other genes involved in arginine 
methylation of FET proteins should still be considered as 
candidates for genetic studies in FTLD-FUS.
Despite the fact that some studies have reported that 
hypomethylation favours protein aggregation [42, 45, 
58], our data do not support the idea that the hypo-
methylation of FET proteins makes them more prone to 
aggregate. In contrast, our present study strengthens the 
hypothesis that deposition of the FET proteins in FTLD-
FUS may be caused/favoured by the higher affinity of 
both UMA and MMA FUS to Transportin-1. Thus, we 
speculate that UMA and MMA FET proteins present in 
FTLD-FUS may lead to irreversible FET-Transportin-1 
binding and eventually co-deposition of these proteins 
in cytoplasmic and intranuclear neuronal and glial inclu-
sions. However, alternative mechanisms (such as phos-
phorylation of FUS) may contribute to FUS redistribution 
and its subsequent pathological deposition in FTLD-FUS 
[8].
In conclusion, this study describes the first PTM specifi-
cally associated with FTLD-FUS, namely MMA FUS. We 
demonstrate that MMA FUS and UMA FUS deposition are 
pathological hallmarks of FTLD-FUS that are not found in 
ALS-FUS caused by FUS mutations. This reinforces the 
idea that the two diseases are most likely caused by differ-
ent pathomechanisms (Table 2) [12] and that loss of proper 
arginine methylation of the FET proteins may be involved 
in FTLD-FUS pathology. Furthermore, we highlight the 
fact that FET proteins are not only dimethylated or unmeth-
ylated, but there is a novel so far overlooked posttransla-
tional modification of FUS (MMA FUS), whose exact bio-
logical and pathological role needs to be elucidated in the 
future.
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